BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hemophilia Alliance
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241204T120000
DTEND;TZID=America/New_York:20241204T130000
DTSTAMP:20260531T111613
CREATED:20241101T160243Z
LAST-MODIFIED:20241101T163332Z
UID:69334-1733313600-1733317200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Sanofi On Real World Surgical Experiences with Altuviiio
DESCRIPTION:Date: Wednesday\, December 4\, 2024\nTime: 12:00pm – 1:00pm ET \n \n  \n  \n  \n \nTopic: \nReal World Surgical Experiences with Altuviiio \nDescription: \nThis program will focus on sharing real-world experiences with Altuviiio\, especially within a surgical context. We’ll kick things off with an introduction to Altuviiio\, followed by some in-depth discussions on surgical experiences. We’ll wrap up with a summary and a Q&A segment\, which I’m sure will spark some great conversations! \nSpeaker: \nShveta Gupta\, MD \n \nShveta Gupta\, MD\, is a Pediatric Hematologist Oncologist and Medical Co-Director at Alliance OBGYN. Dr. Gupta also serves a the Medical Director for IQVIA. \nDr. Gupta received her medical degree with honors and distinction from All India Institute of Medical Sciences in New Delhi\, India. She completed both an internship and residency in pediatrics at Children’s Hospital Los Angeles\, where she also completed a fellowship in hematology oncology. Her primary clinical interests include sickle cell disease as well as bleeding and clotting disorders\, including hemophilia and von Willebrand disease. In addition\, she pursued further training in transfusion medicine and coagulation disorders at Baylor College of Medicine in Houston where she acquired additional expertise in urgent hemotherapy and coagulation consultation in critically ill pediatric patients. \nIn 2016-2017\, Dr. Gupta served as chair of the Hemostasis and Thrombosis Research Society Fellows Network. She is a member of the American Society of Hematology\, the Hemostasis and Thrombosis Research Society\, and the American Association of Blood Banks.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-sanofi-on-real-world-surgical-experiences-with-altuviiio/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/06/Sanofi-New-Logo.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241211T130000
DTEND;TZID=America/New_York:20241211T140000
DTSTAMP:20260531T111613
CREATED:20241126T181513Z
LAST-MODIFIED:20241126T182239Z
UID:69641-1733922000-1733925600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from CSL Behring - Learn about HEMGENIX from the patient perspective
DESCRIPTION:Date: Wednesday\, December 11\, 2024\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nTOPIC: \nLearn about HEMGENIX from the patient perspective \nOBJECTIVE: \nMichael will share his personal experience after receiving HEMGENIX \nRECOMMENDED AUDIENCE: \nHTC providers\, social workers\, administration and support staff \nSPEAKER: \nMichael – Common Factors Advocate Hemophilia B \n \nMy Life at a Glance – At the age of four\, I was diagnosed with hemophilia B factor IX deficiency. My parents told me that this disorder would limit me and that I would most likely have to progress through life with caution. So\, at a very young age\, I was forced to make an adult decision. I had to either learn how to manage \n my hemophilia or accept the possible limitations that were awaiting a severe hemophiliac. When I was a kid\, I made sure to not let hemophilia get in the way by staying on top of managing it. It was hard to accept help from anyone because I wanted to do it on my own. It was my superpower\, not theirs. \nMy previous local support group was amazing. They organized scholarships and had activities that were safe for hemophilia patients. It was a close-knit community. I even volunteered there! After finding the right treatment for me\, I have noticed myself living a more stress-free lifestyle; I no longer have to infuse a minimum of twice a month to maintain my factor levels. \nMy Message to the Community – Hemophilia is our superpower. It’s time to don that cape and advocate for yourself.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-csl-behring-learn-about-hemgenix-from-the-patient-perspective/
CATEGORIES:Members Only
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2023/12/CSL-Behring.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241217T150000
DTEND;TZID=America/New_York:20241217T160000
DTSTAMP:20260531T111613
CREATED:20241126T182846Z
LAST-MODIFIED:20241126T182846Z
UID:69645-1734447600-1734451200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Pfizer on HYMPAVZI: An anti-tissue factor pathway inhibitor
DESCRIPTION:Date: Tuesday\, December 17\, 2024\nTime: 3:00pm – 4:00pm ET \n \n  \n  \n  \n  \n \nTOPIC: \nHYMPAVZI: An anti-tissue factor pathway inhibitor \nOBJECTIVE: \nTo educate attendees on the novel mechanism of action of HYMPAVZI\, the Ph3 clinical trial results and indicated dosage and administration. \nINTENDED AUDIENCE: \nHCP \nSPEAKER: \nDr. Jennifer Schumacher\, PhD\, Senior Medical Director\, Hemophilia \n \nJennifer Schumacher Sr. Medical Director has over 21 years of Medical Affairs and Biotech Industry experience. Currently\, a senior medical director in hemophilia\, Jennifer is the US medical lead for marstacimab. During her tenure at Pfizer\, she has held several positions beginning in US Medical Affairs in Oncology and transitioning to medical director in Rare Disease where she has lead the global medical team for transthyretin amyloid (ATTR) cardiomyopathy and served as publications lead. Jennifer joined the US hemophilia medical team in 2023. \nJennifer received her PhD in Pharmacology from the University of Minnesota\, Minneapolis\, USA and a B.S. in Biotechnology and Chemistry from St. Cloud State University\, St. Cloud\, USA. \nJennifer is based in Minneapolis\, Minnesota and enjoys spending time with her husband and two children. She loves reading\, cooking and the great outdoors\, snowmobiling in the winter and spending time with family and friends at their cabin in the summer.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-pfizer-on-hympavzi-an-anti-tissue-factor-pathway-inhibitor/
CATEGORIES:Members Only
ATTACH;FMTTYPE=image/jpeg:https://hemoalliance.org/wp-content/uploads/2024/01/Pfizer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20241218T130000
DTEND;TZID=America/New_York:20241218T140000
DTSTAMP:20260531T111613
CREATED:20241101T163407Z
LAST-MODIFIED:20241101T163925Z
UID:69340-1734526800-1734530400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Novo Nordisk - Unmet Needs in Current Hemophilia Care: From Burdens to Breakthroughs
DESCRIPTION:Date: Wednesday\, December 18\, 2024\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nTitle: \nUnmet Needs in Current Hemophilia Care: From Burdens to Breakthroughs \nDescription and Session Objectives: \nTo provide a clinical overview of the cost and treatment burden across all hemophilia types\, the experience with current therapy\, and unmet needs that may be addressed with novel therapies. \nTarget Audience: \nAll HTC Staff \nSpeakers: \nParin Chikani PharmD\, MBA \nRyan Rodriguez PharmD\, MS\, BCPS \n \nParin Chikani\, lives in the Chicagoland area and earned his Doctorate of Pharmacy degree from the University of Illinois at Chicago\, College of Pharmacy and his MBA from Kellstadt Graduate School of Business. Before joining Novo Nordisk\, Parin had been in the Pharmacy/Managed Care setting for over 15 years where he held many different roles and leadership positions within Pharmacy and Medical areas of the business. At Novo Nordisk\, one of his roles and responsibilities is to ensure payors and clinicians are up-to-date on evidence based clinical and scientific information in the areas of Rare Diseases to help assist them with patient care. \n \nRyan Rodriguez is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders\, aligning with his passion for evidence-based patient care. Prior to joining Novo Nordisk\, Ryan earned his PharmD degree from the University of Florida\, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy\, where he also earned his Master’s degree in epidemiology. Throughout his career\, Ryan has been involved in medical communications\, evidence generation and publication\, and formulary management for various public and private entities.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-novo-nordisk-unmet-needs-in-current-hemophilia-care-from-burdens-to-breakthroughs/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2023/09/Standard-Manufacturing-Partners-Novo_width_191px.png
END:VEVENT
END:VCALENDAR